

5 February 2025

Fevertree Drinks plc
("Fever-Tree" or the "Company")
Completion of Share Issuance to Molson Coors

Fevertree Drinks plc ("**Fever-Tree**" or the "**Company**") announces today the completion of the issuance of equity to Molson Coors Beverage Company ("**Molson Coors**") following the announcement of the strategic partnership between Fever-Tree and Molson Coors on 30 January 2025.

As announced on 30 January 2025, the equity issuance of ordinary shares of £0.0025 each in the Company ("**Ordinary Shares**") comprises the issuance of 10,856,628 Ordinary Shares (the "**Issuance Shares**") in the Company at an issue price of 654.2 pence per Ordinary Share (together, the "**Issuance**").

Application has been made for the Issuance Shares to be admitted to trading on AIM ("**Admission**"). It is expected that Admission will become effective at 8.00 a.m. today, 5 February 2025. The Issuance Shares will be issued credited as fully paid and will rank pari passu in all respects with the existing Ordinary Shares.

Following Admission, the total number of Ordinary Shares in issue will be 127,615,093. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares with voting rights will be 127,615,093. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

The resultant new significant shareholdings in the Company, following completion of the Issuance, are set out below.

Name	Previous holding	Previous percentage holding of issued share capital	Resultant holding	Resultant percentage holding of enlarged issued share capital on Admission
Molson Coors Beverage Company	-	-	10,856,628	8.5%

For further information:

Fever-Tree

Investor queries

Ann Morris-Gibbons, Director of Investor Relations I ann.hyams@fever-tree.com I +44 (0)7435 828 138

Media queries

Oliver Winters, Director of Communications I oliver.winters@fever-tree.com I +44 (0)770 332 9024

Nominated Advisor and Broker - Investec Bank plc

David Flin I +44 (0)20 7597 5970

Financial Adviser & Corporate Broker - Morgan Stanley & Co. International plc

Henry Stewart I Andrew Foster I Jessica Pauley I +44 (0)20 7425 8000

Corporate Broker - Jefferies International Limited

Ed Matthews I Richard Taylor I +44 (0)20 7029 8000

Financial PR advisers - FGS Global

About Fever-Tree:

Fever-Tree is the world's leading supplier of premium carbonated mixers for alcoholic spirits by retail sales value, with distribution to over 90 countries worldwide. Based in the UK, the brand was launched in 2005 to provide high quality mixers which could cater to the growing demand for premium spirits, in particular gin, but also increasingly for vodka, rum and whisky. The Company sells a range of carbonated mixers to hotels, restaurants, bars and cafes ("On Trade") as well as selected retail outlets ("Off Trade").

Forward-looking statements

This Announcement may contain certain statements about the future outlook for Fever-Tree. Although the directors believe their expectations are based on reasonable assumptions, any statements about future outlook may be influenced by factors that could cause actual outcomes and results to be materially different.

Additional information

This Announcement is made for information purposes only and does not constitute an offer to sell or issue or solicitation to buy, subscribe for or otherwise acquire shares in Fevertree Drinks plc in any jurisdiction in which any such offer or solicitation would be unlawful.

The securities discussed herein are not and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States, unless registered under the Securities Act, or pursuant to an exemption from, or in a transaction not subject to, registration under the Securities Act. No public offering of the securities discussed herein is being made in the United States and the information contained herein does not constitute an offering of securities for sale in the United States and the Company does not currently intend to register any securities under the Securities Act.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCFFFILFVISIIE